Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study. Lapucci C, Frau J, Cocco E, Coghe G, et al. Mult Scler 2024 Aug 14:13524585241266509. doi: 10.1177/13524585241266509.

Read + Share

Amedeo Smart

Independent Medical Education

Lapucci C, Frau J, Cocco E, Coghe G, et al. Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study. Mult Scler 2024 Aug 14:13524585241266509. doi: 10.1177/13524585241266509.
PMID: 39143825